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Abstract
Thirty-seven patients were submitted to kidney transplantation after
transfusion at 2-week intervals with 4-week stored blood from their
potential donors. All patients and donors were typed for HLA-A-B
and DR antigens. The patients were also tested for cytotoxic antibod-
ies against donor antigens before each transfusion. The percentage of
panel reactive antibodies (PRA) was determined against a selected
panel of 30 cell donors before and after the transfusions. The patients
were immunosuppressed with azathioprine and prednisone. Rejection
crises were treated with methylprednisolone. The control group con-
sisted of 23 patients who received grafts from an unrelated donor but
who did not receive donor-specific pretransplant blood transfusion.
The incidence and reversibility of rejection episodes, allograft loss
caused by rejection, and patient and graft survival rates were deter-
mined for both groups. Non-parametric methods (chi-square and
Fisher tests) were used for statistical analysis, with the level of
significance set at P<0.05. The incidence and reversibility of rejection
crises during the first 60 post-transplant days did not differ significant-
ly between groups. The actuarial graft and patient survival rates at five
years were 56% and 77%, respectively, for the treated group and
39.8% and 57.5% for the control group. Graft loss due to rejection was
significantly higher in the untreated group (P = 0.0026) which also
required more intense immunosuppression (P = 0.0001). We conclude
that tranfusions using stored blood have the immunosuppressive
effect of fresh blood transfusions without the risk of provoking a
widespread formation of antibodies. In addition, this method permits
a reduction of the immunosuppressive drugs during the process with-
out impairing the adequate functioning of the renal graft.
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Introduction
In the early eighties, a time when blood
tranfusion protocols were still used as a means
of patient preparation for kidney transplan-
tation (1), we conducted an investigation
involving the possible effects of pretransplant
blood transfusions using whole donor-spe-
cific stored blood as a means of reducing the
degree of patient allogenic sensitization ob-
served after tranfusion of fresh blood. Blood
storage was first reported by Opelz et al. in
1981 (2). The effect of reduced sensitization
seemed to be related to the loss of leucocytes
and platelets containing large amounts of
HLA antigens.
Light et al. (3,4) analyzed the character-
istics of leucocytes obtained from serial units
of human blood stored for a minimum period
of 3 days which were found in a progres-
sively reduced number as storage time in-
creased. The serial study of cells obtained by
separation using a Ficoll Hypaque gradient
and stained with acid peroxidase revealed
that up to the 8th day of storage most cells
were found to be degranulated neutrophils
and not mononuclear cells. Analysis of such
cellular preparation using a “fluorescence
activated cell sorter” (FACS) indicated the
rapid loss of T lymphocytes, granulocytes
and platelets with preservation of B lympho-
cytes and monocytes. After 2-week storage
less than 15% T lymphocytes (OKT3) (cells
containing large amounts of class I MHC
antigens) were present in the samples. The
study of immunogenicity revealed that cells
containing large amounts of class II MHC
antigens (monocytes and B lymphocytes)
had a stimulating activity in a mixed lym-
phocyte culture (MLC) and produced a strong
response in a sensitized lymphocyte assay
(PLT) throughout the storage time (30 days).
In parallel, an in vivo experiment carried
out with Rhesus monkeys indicated that prac-
tically all animals submitted to three whole
blood transfusions using stored blood (up to
2 weeks) developed lymphocytotoxic anti-
bodies compared to about 50% of the mon-
keys transfused with blood stored for 3 or 4
weeks. Although the degree of RhLA in-
compatibility between donor and recipient
of blood transfusions has not been men-
tioned, this finding indicated an inverse rela-
tionship between blood immunogenicity and
storage time (5). Nevertheless, the question
rose of whether stored blood would be as
effective as fresh blood to enhance allograft
survival. Later, the same investigators (6)
demonstrated that previous blood transfu-
sions using stored blood inhibit the sensiti-
zation of Rhesus monkeys to fresh blood,
suggesting a possible immunomodulating
effect on the immune response.
In our experience, this program involv-
ing three donor-specific blood transfusions
using blood stored for four weeks and trans-
fused into unrelated recipients proved to be
successful since the observed sensitization
rate was only 4.1% when evaluated by the
standard NIH crossmatch technique (7). Pa-
tients thus treated received the kidney from
their specific donors.
The objective of the present study was to
analyze the evolution of these patients by
comparing them with a control group of
patients who had received grafts from unre-
lated donors without previous donor-specif-
ic blood transfusions.
Patients and Methods
DST-treated group
Starting in 1983, 37 patients were sub-
mitted to kidney transplantation and received
grafts from unrelated living donors after three
blood transfusions using blood stored for
four weeks, a procedure known as donor-
specific blood transfusion (DST).
All patients and donors underwent HLA-
A-B and DR antigen typing and the recipi-
ents were tested for anti-donor antigen cyto-
toxic antibodies prior to each transfusion.
The percentage of panel reactive antibodies
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(PRA) was determined before and at the end
of the blood transfusions. Transplantation
was performed about 19 days after the last
blood transfusion.
Transfusions
Two hundred ml blood was obtained from
the donor in CPDA-1 (citrate-phosphate-dex-
trose-adenine) and stored at 4oC for four
weeks prior to transfusion. The transfusions
were performed at 15-day intervals. The pa-
tients were submitted to the usual hemodi-
alysis session at least 48 h after each blood
transfusion. Occasional dialysis transfusions
were interrupted 15 days prior to the begin-
ning of the program.
Immunosuppressive therapy
As post-transplant immunosuppressive
therapy the patients received only azathio-
prine and prednisone. In some cases of low
tolerance (hepatotoxicity or myelotoxicity),
azathioprine was replaced with cyclosporine
A. Rejection episodes were treated with
methylprednisolone pulses (1 g/day for 3
days).
Azathioprine was instituted 48 h before
kidney transplantation at a dose of 5 mg kg-1
day-1. On the third postoperative day the
dose was reduced to 3 mg kg-1 day-1. The
maintenance dose after one year ranged from
0.22 to 2.8 mg kg-1 day-1 depending on fac-
tors such as tolerance, age, early post-trans-
plant evolution, and data concerning pre-
transplant immunologic condition (retrans-
plant, number of random transfusions, panel
and number of previous pregnancies). Six
patients were maintained on a dose of 1 mg
kg-1 day-1 azathioprine or less for a period of
3 to 60 months.
Prednisone therapy was initiated on the
day of transplantation at a dose of 1.5 mg kg-1
day-1 and was slowly reduced to a mainte-
nance dose of 12.5 to 15 mg/day one year
after transplantation, and 7.5 to 12.5 mg/day
two years postoperatively. Three patients
were maintained on corticosteroid mono-
therapy for 3, 6 and 30 months. Patients on
monotherapy or on low doses of azathio-
prine (<1 mg kg-1 day-1) received higher
doses of prednisone (15 to 20 mg/day).
In cases requiring cyclosporine the doses
were established for each patient so as to
obtain serum concentrations of 120 ng/ml or
lower.
Control group
The control group consisted of 23 pa-
tients who received grafts from unrelated
living donors but who did not undergo do-
nor-specific pretransplant blood transfusion.
A double immunosuppressive scheme (aza-
thioprine and prednisone) was used in 5
patients, and a triple therapy (azathioprine,
prednisone and cyclosporine) was used in 18
patients. Two of these 18 patients also re-
ceived monoclonal antibodies. Time since
transplantation coincided with that of pa-
tients receiving stored blood. The two groups
were compared regarding age, sex, dialysis
time, total number of random transfusions
and previous pregnancies, previous trans-
plantation and immunosuppressive therapy
(Table 1). The incidence and reversibility of
rejection episodes, allograft loss caused by
Table 1 - Comparison between DST-treated (transfused group) and control
(nontransfused group) patients.
*Two of 18 patients received quadruple therapy. NS, Nonsignificant.
Parameters DST-treated (N = 37) Control (N = 23) P value
Age (years) 39.41 – 10.77 42.00 – 13.63 NS
Male/female 21/16 18/5 NS
Time on dialysis (months) 28.63 – 13.22 19.40 – 15.59 NS
Random transfusions/patient 28/37 20/23 NS
(number of transfused patients)
Pregnancies 32/12 0/5 0.0062
Retransplant 2/37 5/23 NS
Immunosuppressive therapy
double 34/37(91.8%) 5/23 (21.7%) 0.0001
triple 3/37 (8.1%) 18*/23 (78.2%) 0.015
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rejection, and patient and graft survival rates
were determined for both groups.
Non-parametric methods (chi-square and
Fisher tests) were used for statistical analy-
sis, with the level of significance set at
P<0.05.
Results
There was no significant change in per-
cent reactivity to the panel between the re-
sults obtained before and after transfusion.
In two patients the crossmatch became nega-
tive following blood transfusion.
Rejection episodes
The incidence and reversibility of rejec-
tion crises during the first 60 post-transplant
days (early rejections) did not differ signifi-
cantly between groups. Two months post-
transplant (late rejection), six rejection cri-
ses occurred in the treated group (6/37;
16.2%), four of which were due to interrup-
tion of immunosuppressive therapy, and one
to cytomegalovirus infection. There were
three complete reversals. Ten rejection epi-
sodes with three partial reversals were ob-
served in the control group (10/23; 43.4%)
(P = 0.0432) (Table 2). Rejection episodes
after two months were significantly less fre-
quent in the DST-treated group.
Survival rates
The actuarial graft and patient survival
rates at five years were 56% and 77%, re-
spectively, for the treated group and 39.8%
and 57.5% for the control group (Figure 1B
and 1A).
Graft loss due to rejection was signifi-
cantly higher in the control group. In the
DST-treated group there were eight deaths
during the study period, all involving pa-
tients with functioning grafts, and seven graft
losses, only three (3/37; 8.1%) of which
were due to rejection consequent to discon-
tinuation of immunosuppressive therapy. In
the control group, twelve patients died, four
with their renal function preserved. The re-
maining control patients showed chronic re-
jection and three allograft losses, one of
which was due to nephrotoxicity resulting
from cyclosporine treatment (10/23; 43.4%)
(Table 2). There was a considerably higher
number of graft losses due to rejection in the
control group.
Retransplant
In the DST-treated group, two patients
were retransplanted and both maintained
normal renal function 87 and 99 months
after transplantation. In the control group,
five patients were retransplanted. Of these,
one lost the kidney due to acute transplant
vasculopathy 17 days after transplantation,
and two lost the graft due to chronic rejec-
tion 18 and 48 months after transplantation.
In the DST-treated group the patients sub-
mitted to retransplant had a better outcome
than the retransplanted patients in the con-
trol group.
Monotherapy and low doses of
immunosuppressive drugs
The three patients in the transfused group
maintained on monotherapy with prednisone
(Figure 2A,B,C) or those who were kept on
Table 2 - Evolution of DST-treated (transfused
group) and control (nontransfused group) patients.
NS, Nonsigificant.
Events DST-treated Control P value
(N = 37) (N = 23)
Early rejections 25/17 26/15 NS
(crisis/patient) (45.9%) (65.2%)
Reversed 24/25 22/26 NS
crises (96.0%) (84.6%)
Late 6/37 10/23 0.0432
rejections (16.2%) (43.4%)
Kidney loss 3/37 10/23 0.0026
by rejection (8.1%) (43.4%)
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low doses of azathioprine (<1 mg kg-1 day-1)
did not show changes in renal function dur-
ing this period of treatment. It should be
noted that the DST-treated patients needed
fewer immunosuppressive drugs (double
therapy, 34/37; 91.8%) than the control group
(5/23; 21.7%), in addition to tolerating lower
doses during treatment.
Discussion
The protocols used by Light et al. (8) and
Whelchel et al. (9) for humans, although
based on transfusions that were specific for
the donor of the kidney transplant, did not
permit an evaluation of the effect of time of
blood storage on the survival of the renal
allograft. The first group of authors adminis-
tered to each patient three whole blood trans-
fusions using blood stored for 1, 3 and 5
weeks; the second group of investigators
performed blood transfusions using blood
with 2, 14, 21 and 28 days of storage. In both
cases, the initial tranfusion was found to
have caused enough allogenic stimulation
(immunogenic) to prevent a possible tolero-
genic effect caused by later transfusions.
Our patients received three donor-specif-
ic transfusions of blood stored for identical
periods of time. The low incidence of rejec-
tion episodes during the first 60 post-trans-
plant days and the good response to standard
therapy suggest a protective effect of stored
blood transfusion during the early post-trans-
plant period. It is known that after transfu-
sion there occurs an increase in the produc-
tion of PGE-2 by macrophages, with this
increase being more pronounced the longer
the storage of the transfused product (10,11).
Prostaglandin levels usually remain high for
three months post-transfusion (12). An analo-
gous fact occurs regarding function of the
suppressor cells whose activity intensifies
after blood transfusion, returning to former
levels four weeks after transfusion (10,13,14).
These findings led us to believe that trans-
plantation should be performed soon after
the last transfusion for the patient to benefit
from the nonspecific protection of the me-
diators induced by transfusion. Furthermore,
since we are dealing here with potentially
sensitized patients, adequate immunosup-
pression should be provided during the early
post-transplant period to assure the deletion
of the immunologically active cellular clones,
thus permitting the anti-idiotype antibodies
to develop (15,16).
The number of late rejections was signif-
icantly smaller in the transfused group than
in the nontransfused group (P = 0.0432) and
the same was observed regarding graft losses
due to rejection (treated group: 8.1% vs
43.4% in control group, P = 0.0026).
The effect of transfusion seems to be
long lasting. In the present study it was pos-
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sible to keep some of the patients on reduced
doses of azathioprine, and three on mono-
therapy with corticosteroids for a period of 3
to 30 months.
Other investigators have suggested
(17,18) that a certain HLA mismatching grade
(non-HLA-sharing) between donor and re-
cipient, mainly concerning class II antigens,
is necessary to obtain the transfusion effect
and to induce enhancement of allograft sur-
vival. The protocol reported here is probably
more suitable for transplantation involving
non-consanguineous individuals.
Blood is a multisubstance complex, and
consequently is apt to interfere with the im-
mune response in several ways. Transfusion
of erythrocytes can result in immunologic
unresponsiveness and a better outcome for
the transplant (19). The senescent red blood
cell exposes an antigen (neoantigen) that
makes it immunogenic. Immunoglobulins,
especially IgG, attach themselves to the cell
membrane rendering the cell vulnerable to
phagocytosis. The neoantigen that emerges
in the senescent erythrocyte also occurs on
other somatic cells including cells of the
proximal renal tubule (20,21).
The quantity of IgG found on the erythro-
cyte surface increases with storage time. The
neoantigen is likely to play a role in the
effect of tranfusion using stored blood. Anti-
gen features and means of display most prob-
ably are important for its effect on the im-
mune response. When we consider the fact
that, upon administration of stored blood,
ruptured leukocytes and red blood cells are
being transferred into the recipient it is rea-
sonable to assume that a large amount of
class I soluble antigens, once in the blood
stream, are able to promote the appropriate
emergence of antigens so as to induce toler-
ance.
Stored blood contains microaggregates
of fibrin residues, degenerate leukocytes and
blood platelets that bind to fibronectin caus-
ing a significant decrease in serum concen-
trations of this molecule, and consequently
leading to insufficient macrophage activity.
Besides playing a role in macrophage func-
tion, fibronectin is a surface molecule closely
involved in cell adhesion, activation and
migration (22,23).
Mincheff et al. (24) have shown that
blood stored for 13 or more days loses its
immunogenicity because its ability to pres-
ent the accessory signal diminishes, with a
Figure 2 - Transfused patients maintained on monotherapy with prednisone for 3 (A), 6 (B)
and 30 (C) months.
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consequent induction of some degree of im-
munosuppression.
Blood storage and the resulting loss of
ability by presenting cells (APC) to express
the costimulatory signals impair the direct
presentation of alloantigens to recipient T
cells. The indirect presentation by recipient
APC is important whether alloantigens are
in a solubilized form or expressed on the
membrane of donor cells. As the storage of
blood progresses the cells undergo second-
ary necrosis with a loss of membrane integ-
rity. Mincheff et al. (25), working with an
inbred rodent model, transfused intrave-
nously necrotic, apoptotic or viable alloge-
neic cells and achieved immunosuppression
after administration of necrotic cells.
Probably several factors intervene in the
effect of transfusion with variable intensity
and at different moments after the trans-
plant. We conclude that the present method
allows a reduction of immunosuppressive
drugs without risking the good function of
the renal allograft. The practical implication
of good results with DST using stored blood
is the availability of a larger number of po-
tential living donors for kidney transplanta-
tion.
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